Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.

Telomerase is essential for immortalization of most human cancer cells. Expression of the core telomerase RNA (hTR) and reverse transcriptase (hTERT) subunits is mainly regulated by transcription. However, hTR transcriptional regulation remains poorly understood. We previously showed that the core hTR promoter is activated by Sp1 and is repressed by Sp3. Here, we show that the mitogen-activated protein kinase kinase kinase 1 (MEKK1)/c-Jun-NH(2)-kinase (JNK) pathway represses hTR expression by a mechanism that involves Sp1 and Sp3. Promoter activity was induced by the JNK inhibitor SP600125 and was repressed by activated MEKK1. Repression by MEKK1 was blocked by SP600125 or enhanced by coexpression of wild-type but not phosphoacceptor mutated JNK. SP600125 treatment also increased levels of endogenous hTR. Mutations in the hTR promoter Sp1/Sp3 binding sites attenuated SP600125-mediated promoter induction, whereas coexpression of MEKK1 with Sp3 enhanced hTR promoter repression. Chromatin immunoprecipitation showed that levels of immunoreactive Sp1 associated with the hTR promoter were low in comparison with Sp3 in control cells but increased after JNK inhibition with a reciprocal decrease in Sp3 levels. No corresponding changes in Sp1/Sp3 protein levels were detected. Thus, JNK represses hTR promoter activity and expression, apparently by enhancing repression through Sp3.

[1]  D. Mukhopadhyay,et al.  Activation of Sp1-mediated Vascular Permeability Factor/Vascular Endothelial Growth Factor Transcription Requires Specific Interaction with Protein Kinase C ζ* , 1998, The Journal of Biological Chemistry.

[2]  R. Perona,et al.  Cisplatin induces a persistent activation of JNK that is related to cell death , 1998, Oncogene.

[3]  T. Vulliamy,et al.  A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria , 2004, BMC blood disorders.

[4]  R. Glasspool,et al.  Activation of telomerase rna gene promoter activity by NF-Y, Sp1, and the retinoblastoma protein and repression by Sp3. , 2000, Neoplasia.

[5]  Q. Xu,et al.  Sp1 Increases Expression of Cyclooxygenase-2 in Hypoxic Vascular Endothelium , 2000, The Journal of Biological Chemistry.

[6]  W. Folk,et al.  MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. , 2004, Blood.

[7]  A. V. D. Van Der Zee,et al.  Lack of telomerase RNA gene hTERC expression in alternative lengthening of telomeres cells is associated with methylation of the hTERC promoter. , 2001, Cancer research.

[8]  February 1 , 1966 .

[9]  S. Kaye,et al.  Is small cell lung cancer the perfect target for anti-telomerase treatment? , 1999, Carcinogenesis.

[10]  J. Riou,et al.  Telomerase: a therapeutic target for the third millennium? , 2000, Critical reviews in oncology/hematology.

[11]  S. Kaye,et al.  Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization , 1998, Oncogene.

[12]  J. Shay,et al.  Telomerase inhibitors. , 2001, Trends in biotechnology.

[13]  A. V. D. Van Der Zee,et al.  hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents , 1997, Oncogene.

[14]  T. Vulliamy,et al.  The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita , 2001, Nature.

[15]  E. Yazlovitskaya,et al.  Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines , 2000, Molecular carcinogenesis.

[16]  I. Ganly,et al.  Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase , 2003, Oncogene.

[17]  J. Merchant,et al.  EGF stimulates gastrin promoter through activation of Sp1 kinase activity. , 2000, American journal of physiology. Cell physiology.

[18]  R. DePinho,et al.  Essential role of mouse telomerase in highly proliferative organs , 1998, Nature.

[19]  R. Tjian,et al.  GC box binding induces phosphorylation of Sp1 by a DNA-dependent protein kinase , 1990, Cell.

[20]  Xiao-Fan Wang,et al.  Transcriptional Activation of p 21 waf 1 / cip 1 by Alkylphospholipids : Role of the Mitogen-Activated Protein Kinase Pathway in the Transactivation of the Human p 21 waf 1 / cip 1 Promoter by Sp 1 , 2004 .

[21]  R. W. Leggett,et al.  Casein Kinase II-mediated Phosphorylation of the C Terminus of Sp1 Decreases Its DNA Binding Activity* , 1997, The Journal of Biological Chemistry.

[22]  D. Adams,et al.  The liver: a model of organ-specific lymphocyte recruitment , 2002, Expert Reviews in Molecular Medicine.

[23]  R. Glasspool,et al.  Telomerase-specific suicide gene therapy vectors expressing bacterial nitroreductase sensitize human cancer cells to the pro-drug CB1954 , 2001, Oncogene.

[24]  Jiangqin Zhao,et al.  MDM2 negatively regulates the human telomerase RNA gene promoter , 2005, BMC Cancer.

[25]  E. K. Parkinson,et al.  Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer , 1997, Oncogene.

[26]  J. Pouysségur,et al.  Identification of Two Sp1 Phosphorylation Sites for p42/p44 Mitogen-activated Protein Kinases , 2002, The Journal of Biological Chemistry.

[27]  María A Blasco,et al.  Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA , 1997, Cell.

[28]  R. Glasspool,et al.  Telomerase and cancer: time to move from a promising target to a clinical reality , 2001, The Journal of pathology.

[29]  M. Cobb,et al.  Mitogen-activated protein kinase pathways. , 1997, Current opinion in cell biology.

[30]  E. Parkinson,et al.  Cloning and characterization of human and mouse telomerase RNA gene promoter sequences , 1998, Oncogene.

[31]  A. Bilsland,et al.  Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies , 2004, Nature Clinical Practice Oncology.

[32]  T. Vulliamy,et al.  Heterozygous telomerase RNA mutations found in dyskeratosis congenita and aplastic anemia reduce telomerase activity via haploinsufficiency. , 2004, Blood.

[33]  R. Glasspool,et al.  Telomerase-directed molecular therapeutics , 2002, Expert Reviews in Molecular Medicine.

[34]  F. Bachand,et al.  Functional Regions of Human Telomerase Reverse Transcriptase and Human Telomerase RNA Required for Telomerase Activity and RNA-Protein Interactions , 2001, Molecular and Cellular Biology.

[35]  W. Keith,et al.  Expression of telomerase RNA in oesophageal and oral cancer. , 2001, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[36]  W. Keith,et al.  Analysis of telomerase RNA gene expression by in situ hybridization. , 2002, Methods in molecular biology.

[37]  Margaret A. Strong,et al.  Haploinsufficiency of mTR results in defects in telomere elongation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[38]  G. Gores,et al.  Bile Acids Up-regulate Death Receptor 5/TRAIL-receptor 2 Expression via a c-Jun N-terminal Kinase-dependent Pathway Involving Sp1* , 2004, Journal of Biological Chemistry.

[39]  Jiangqin Zhao,et al.  Involvement of NF‐Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene , 2003, FEBS letters.

[40]  C. Autexier,et al.  Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA. , 1996, The EMBO journal.

[41]  H. Hollema,et al.  Telomerase in (pre)neoplastic cervical disease. , 2000, Human pathology.

[42]  A. Depaoli-Roach,et al.  Dephosphorylation of Sp1 by Protein Phosphatase 1 Is Involved in the Glucose-mediated Activation of the Acetyl-CoA Carboxylase Gene* , 1996, The Journal of Biological Chemistry.

[43]  K. Webster,et al.  Hypoxia Regulates β-Enolase and Pyruvate Kinase-M Promoters by Modulating Sp1/Sp3 Binding to a Conserved GC Element* , 1998, The Journal of Biological Chemistry.

[44]  G. Krikun,et al.  Regulation of tissue factor gene expression in human endometrium by transcription factors Sp1 and Sp3. , 2000, Molecular endocrinology.

[45]  J. Merchant,et al.  Sp1 phosphorylation by Erk 2 stimulates DNA binding. , 1999, Biochemical and biophysical research communications.

[46]  Shiaw-Yih Lin,et al.  Growth/Cell Cycle Regulation of Sp1 Phosphorylation* , 1999, The Journal of Biological Chemistry.